Fauna Bio Inc. has nominated Faun-1083 as its first development candidate, for the treatment of heart failure with preserved ejection fraction (HFpEF). Faun-1083 is a novel small-molecule therapeutic ...

Faun1083 has demonstrated positive in-vivo efficacy in multiple preclinical animal models, including rat sugen hypoxia and ZSF1 studies, which are common models to study key features of heart failure ...

Alleviant Medical announced that it received FDA investigational device exemption and breakthrough device designation for its ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

2023 ACC HFpEF Guidance: What to Know Ileana Piña, MD, MPH, discusses the Expert Consensus Decision Pathway from ACC focused on the definition, diagnosis, and treatment of heart failure with ...

The company is also evaluating JK08, a bispecific fusion protein formulation, JK10, a bispecific antibody-based drug and JK06, an antibody drug conjugant for the treatment of various oncology ...

According to GlobalData, Phase III drugs for Diastolic Heart Failure (HFpEF) does not have sufficient historical ... Ziltivekimab (COR-001) is under development for the treatment of chronic kidney ...

The administration of potassium nitrate (KNO3) does not improve exercise capacity or quality of life in patients with heart failure with preserved ejection fraction (HFpEF), despite increasing ...

While there’s no cure for autism, there are many approaches that can help both children and adults manage their symptoms and improve their quality of life. Autism spectrum disorder is a ...